IL97720A - Live vaccines - Google Patents

Live vaccines

Info

Publication number: IL97720A
Authority: IL; Israel
Prior art keywords: bacterium; gene; mutation; salmonella; vaccine
Prior art date: 1990-03-30

Application number

IL9772091A

Other languages

English (en)

Hebrew (he)

Other versions

IL97720A0 (en

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-03-30

Filing date

1991-03-28

Publication date

1999-06-20

1991-03-28 Application filed by Wellcome Found filed Critical Wellcome Found

1992-06-21 Publication of IL97720A0 publication Critical patent/IL97720A0/xx

1999-06-20 Publication of IL97720A publication Critical patent/IL97720A/en

Links

229960005486 vaccine Drugs 0.000 title claims description 23
230000035772 mutation Effects 0.000 claims abstract description 37
108090000623 proteins and genes Proteins 0.000 claims abstract description 35
230000002238 attenuated effect Effects 0.000 claims abstract description 28
239000000427 antigen Substances 0.000 claims abstract description 14
102000036639 antigens Human genes 0.000 claims abstract description 14
108091007433 antigens Proteins 0.000 claims abstract description 14
244000005700 microbiome Species 0.000 claims abstract description 13
241000894006 Bacteria Species 0.000 claims description 38
101150007310 htrA gene Proteins 0.000 claims description 34
241000607142 Salmonella Species 0.000 claims description 14
238000012217 deletion Methods 0.000 claims description 11
230000037430 deletion Effects 0.000 claims description 11
241001167018 Aroa Species 0.000 claims description 8
101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 claims description 8
101150037081 aroA gene Proteins 0.000 claims description 8
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 6
-1 aromatic amino acid Chemical class 0.000 claims description 6
208000015181 infectious disease Diseases 0.000 claims description 6
238000003780 insertion Methods 0.000 claims description 5
230000037431 insertion Effects 0.000 claims description 5
230000006696 biosynthetic metabolic pathway Effects 0.000 claims description 4
101100216993 Bacillus subtilis (strain 168) aroD gene Proteins 0.000 claims description 3
241000588807 Bordetella Species 0.000 claims description 3
241000588722 Escherichia Species 0.000 claims description 3
241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims description 3
241000607598 Vibrio Species 0.000 claims description 3
101150042732 aroC gene Proteins 0.000 claims description 3
101150102858 aroD gene Proteins 0.000 claims description 3
101150040872 aroE gene Proteins 0.000 claims description 3
101150108612 aroQ gene Proteins 0.000 claims description 3
230000037361 pathway Effects 0.000 claims description 3
241000606790 Haemophilus Species 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
238000011321 prophylaxis Methods 0.000 claims description 2
108091028043 Nucleic acid sequence Proteins 0.000 abstract description 23
102000004169 proteins and genes Human genes 0.000 abstract description 9
108020004414 DNA Proteins 0.000 abstract description 6
230000004044 response Effects 0.000 abstract description 3
230000006353 environmental stress Effects 0.000 abstract description 2
101150018266 degP gene Proteins 0.000 description 23
210000004027 cell Anatomy 0.000 description 14
241000588724 Escherichia coli Species 0.000 description 13
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 9
241000282414 Homo sapiens Species 0.000 description 8
241000699670 Mus sp. Species 0.000 description 8
229930027917 kanamycin Natural products 0.000 description 8
229960000318 kanamycin Drugs 0.000 description 8
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 8
229930182823 kanamycin A Natural products 0.000 description 8
238000000034 method Methods 0.000 description 8
108010004889 Heat-Shock Proteins Proteins 0.000 description 6
102000002812 Heat-Shock Proteins Human genes 0.000 description 6
101100178822 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) htrA1 gene Proteins 0.000 description 6
101100277437 Rhizobium meliloti (strain 1021) degP1 gene Proteins 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
241001465754 Metazoa Species 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000203 mixture Substances 0.000 description 4
238000002703 mutagenesis Methods 0.000 description 4
231100000350 mutagenesis Toxicity 0.000 description 4
238000011725 BALB/c mouse Methods 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
239000013611 chromosomal DNA Substances 0.000 description 3
230000036039 immunity Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000003550 marker Substances 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
230000003938 response to stress Effects 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000002255 vaccination Methods 0.000 description 3
LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 2
101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 2
241001529936 Murinae Species 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
206010039438 Salmonella Infections Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
125000003275 alpha amino acid group Chemical group 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
238000009505 enteric coating Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000003902 lesion Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000006166 lysate Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
101150091444 ompR gene Proteins 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
101150106872 rpoH gene Proteins 0.000 description 2
206010039447 salmonellosis Diseases 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000011282 treatment Methods 0.000 description 2
101150075472 ycf27 gene Proteins 0.000 description 2
102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
241000242722 Cestoda Species 0.000 description 1
108010059013 Chaperonin 10 Proteins 0.000 description 1
108010058432 Chaperonin 60 Proteins 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
206010016952 Food poisoning Diseases 0.000 description 1
208000019331 Foodborne disease Diseases 0.000 description 1
241000710198 Foot-and-mouth disease virus Species 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
102100023737 GrpE protein homolog 1, mitochondrial Human genes 0.000 description 1
108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 1
102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
108010025076 Holoenzymes Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000829489 Homo sapiens GrpE protein homolog 1, mitochondrial Proteins 0.000 description 1
101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 description 1
229920003085 Kollidon® CL Polymers 0.000 description 1
101150043276 Lon gene Proteins 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
241000244206 Nematoda Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010090127 Periplasmic Proteins Proteins 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
235000014676 Phragmites communis Nutrition 0.000 description 1
239000004365 Protease Substances 0.000 description 1
241000711798 Rabies lyssavirus Species 0.000 description 1
101100235786 Rattus norvegicus Lonp1 gene Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
241001138501 Salmonella enterica Species 0.000 description 1
241001607429 Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 Species 0.000 description 1
102100021119 Serine protease HTRA1 Human genes 0.000 description 1
241000607760 Shigella sonnei Species 0.000 description 1
108010063499 Sigma Factor Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
101710182223 Toxin B Proteins 0.000 description 1
241000242541 Trematoda Species 0.000 description 1
208000037386 Typhoid Diseases 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
235000015241 bacon Nutrition 0.000 description 1
229940031416 bivalent vaccine Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
108010079058 casein hydrolysate Proteins 0.000 description 1
229940030156 cell vaccine Drugs 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
101150092055 envZ gene Proteins 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000013923 monosodium glutamate Nutrition 0.000 description 1
229940031348 multivalent vaccine Drugs 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
229940096978 oral tablet Drugs 0.000 description 1
229940126578 oral vaccine Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
101150028857 phoP gene Proteins 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000012743 protein tagging Effects 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000012552 review Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229940115939 shigella sonnei Drugs 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229940073490 sodium glutamate Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000035882 stress Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
201000008297 typhoid fever Diseases 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/826—Bacterial vaccine for avian species, e.g. poultry or other birds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Immunology (AREA)
Mycology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

IL9772091A 1990-03-30 1991-03-28 Live vaccines IL97720A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB909007194A GB9007194D0 (en)	1990-03-30	1990-03-30	Live vaccines

Publications (2)

Publication Number	Publication Date
IL97720A0 IL97720A0 (en)	1992-06-21
IL97720A true IL97720A (en)	1999-06-20

Family

ID=10673583

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9772091A IL97720A (en)	1990-03-30	1991-03-28	Live vaccines

Country Status (19)

Country	Link
US (2)	US5804194A (de)
EP (1)	EP0524205B1 (de)
JP (1)	JP3054440B2 (de)
KR (1)	KR100202771B1 (de)
AT (1)	ATE157397T1 (de)
CA (1)	CA2079463C (de)
DE (1)	DE69127440T2 (de)
DK (1)	DK0524205T3 (de)
ES (1)	ES2106776T3 (de)
GB (1)	GB9007194D0 (de)
GR (1)	GR3025258T3 (de)
HU (1)	HU217776B (de)
IE (1)	IE911037A1 (de)
IL (1)	IL97720A (de)
MY (1)	MY130001A (de)
NZ (1)	NZ237616A (de)
TW (1)	TW205567B (de)
WO (1)	WO1991015572A1 (de)
ZA (1)	ZA912397B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5662908A (en) *	1985-07-31	1997-09-02	The Board Of Trustees Of The Leland Stanford Jr. University	Invasive microorganisms
CZ285118B6 (cs) *	1991-03-05	1999-05-12	The Wellcome Foundation Limited	Exprese rekombinačních proteinů v oslabených bakteriích
WO1993018165A1 (en) *	1992-03-02	1993-09-16	The Board Of Trustees Of The Leland Stanford Junior University	Microorganisms having attenuated invasiveness
CA2143299A1 (en) *	1992-09-04	1994-03-17	University Of Saskatchewan	Novel bacterial vaccines using vaccine strains of pathogenic bacteria
PT700445E (pt)	1993-06-04	2002-07-31	Whitehead Biomedical Inst	Proteinas de stress e suas utilizacoes
US5997873A (en) *	1994-01-13	1999-12-07	Mount Sinai School Of Medicine Of The City University Of New York	Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) *	1994-01-13	1998-05-12	Mount Sinai School Of Medicine Of The City University Of New York	Immunotherapeutic stress protein-peptide complexes against cancer
GB9401795D0 (en) *	1994-01-31	1994-03-23	Medeva Holdings Bv	Vaccines
US5961979A (en) *	1994-03-16	1999-10-05	Mount Sinai School Of Medicine Of The City University Of New York	Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5985270A (en) *	1995-09-13	1999-11-16	Fordham University	Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) *	1995-09-13	1999-08-10	Fordham University	Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en)	1995-09-13	1998-11-17	Fordham University	Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5796671A (en)	1996-03-01	1998-08-18	Wahlstrom; Sven E.	Dynamic random access memory
US7157089B1 (en)	1996-11-26	2007-01-02	Stressgen Biotechnologies Corporation	Immune responses using compositions containing stress proteins
US5830464A (en) *	1997-02-07	1998-11-03	Fordham University	Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en)	1997-02-07	2000-01-25	Fordham University	Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
BR9812272A (pt)	1997-08-05	2000-07-18	Stressgen Biotechnologies Corp	Respostas imunológicas contra antìgenos de hpv, eliciadas por composições que compreendem um antìgeno de hpv e uma proteìna de tensão ou um vetor de expressão capaz de expressar essas proteìnas
US5948646A (en)	1997-12-11	1999-09-07	Fordham University	Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6905691B1 (en)	1997-12-11	2005-06-14	Celltech Pharma Europe Limited	Vaccines containing attenuated bacteria
CU22661A1 (es) *	1997-12-30	2001-04-27	Cnic Ct Nac Investigaciones	Nuevos candidatos vacunales de vibrio cholerae y método de obtención
ES2439014T3 (es)	1998-02-20	2014-01-21	The University Of Miami	Complejo de péptido antigénico-proteína de choque térmico modificada
GB9806449D0 (en) *	1998-03-25	1998-05-27	Peptide Therapeutics Ltd	Attenuated bacteria useful in vaccines
US6413768B1 (en)	1998-12-02	2002-07-02	University Of Maryland	Expression plasmids
ATE360366T1 (de) *	1998-12-02	2007-05-15	Univ Maryland	Plasmidstabilisierungssystem für die verabreichung von antigenen
US8076130B2 (en)	1998-12-02	2011-12-13	University Of Maryland, Baltimore	Plasmid maintenance system for antigen delivery
US6497880B1 (en)	1998-12-08	2002-12-24	Stressgen Biotechnologies Corporation	Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
FR2787810B1 (fr) *	1998-12-24	2002-10-31	Inst Nat De La Rech Agronomique Inra	Bacteries a gram positif depourvues d'activite proteasique htra, et leurs utilisations
EP1196772A2 (de)	1999-07-08	2002-04-17	Stressgen Biotechnologies Corporation	Induktion einer th1-vermittelten immunantwort in vitro
EP1253939B1 (de)	2000-01-14	2009-08-05	Whitehead Institute For Biomedical Research	Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig
WO2001091787A1 (en)	2000-06-02	2001-12-06	University Of Connecticut Health Center	Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
HRP20021015A2 (en)	2000-06-26	2004-02-29	Stressgen Biotechnologies Corp	Human papilloma virus treatment
US6872547B1 (en)	2000-10-11	2005-03-29	Washington University	Functional balanced-lethal host-vector systems
MXPA03006971A (es)	2001-02-05	2004-05-05	Stressgen Biotechnologies Corp	Tratamiento del virus de hepatitis b.
ITRM20010295A1 (it) *	2001-05-30	2002-12-02	Stresstech S R L	Metodo per ottenere microrganismi patogeni non virulenti attraverso una modificazione dello stato fisico e/o dinamico delle loro membrane bi
RU2335295C2 (ru)	2001-08-20	2008-10-10	Юниверсити Оф Коннектикут Хелт Сентер	Способы получения композиций, включающих хитшоковые белки или альфа-2-макроглобулин, пригодных для лечения злокачественной опухоли и инфекционного заболевания
GB0121998D0 (en)	2001-09-11	2001-10-31	Acambis Res Ltd	Attenuated bacteria useful in vaccines
US7541043B2 (en)	2002-01-16	2009-06-02	The United States Of America As Represented By The Department Of Health And Human Services	Vaccine for protection against Shigella sonnei disease
UA100370C2 (uk)	2006-12-11	2012-12-25	Мериал Лимитед	Спосіб вакцинації птахів проти salmonella
US8475785B2 (en)	2008-03-03	2013-07-02	The University Of Miami	Allogeneic cancer cell-based immunotherapy
WO2009117116A2 (en)	2008-03-20	2009-09-24	University Of Miami	Heat shock protein gp96 vaccination and methods of using same
IL214246B (en) *	2011-07-21	2018-08-30	Shafferman Avigdor	Vaccines produced from htra-defective Bacillus anthraxis
JP2017513849A (ja)	2014-04-15	2017-06-01	グリフィス・ユニバーシティＧｒｉｆｆｉｔｈＵｎｉｖｅｒｓｉｔｙ	Ａ群レンサ球菌ワクチン
KR20170109582A (ko)	2015-02-06	2017-09-29	히트 바이오로직스, 인코퍼레이티드	벡터 공동 발현 백신 및 공동 자극 분자
US11666649B2 (en)	2016-10-11	2023-06-06	University Of Miami	Vectors and vaccine cells for immunity against Zika virus
CA3058938A1 (en)	2017-04-04	2018-10-11	Heat Biologics, Inc.	Intratumoral vaccination
KR20220152402A (ko)	2019-11-25	2022-11-15	그리피스 유니버시티	임균 감염에 대한 면역원성 단백질

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4337314A (en) *	1979-05-23	1982-06-29	Research Corporation	Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US4735801A (en) *	1982-09-07	1988-04-05	Board Of Trustees Of Leland Stanford Jr. University	Novel non-reverting salmonella live vaccines
GB8314645D0 (en) *	1983-05-26	1983-06-29	Wellcome Found	Bivalent vaccines
WO1988005821A1 (en) *	1987-01-30	1988-08-11	President And Fellows Of Harvard College	Periplasmic protease mutants of escherichia coli
US4895717A (en) *	1987-07-10	1990-01-23	The United States Of America As Represented By The Secretary Of Agriculture	Revertant serotype 1 Marek's disease vaccine
GB8730037D0 (en) *	1987-12-23	1988-02-03	Wellcome Found	Vaccines
US5114844A (en) *	1989-03-14	1992-05-19	Yeda Research And Development Co., Ltd.	Diagnosis and treatment of insulin dependent diabetes mellitus
GB8912330D0 (en) *	1989-05-30	1989-07-12	Wellcome Found	Live vaccines

1990
- 1990-03-30 GB GB909007194A patent/GB9007194D0/en active Pending
1991
- 1991-03-28 ES ES91906493T patent/ES2106776T3/es not_active Expired - Lifetime
- 1991-03-28 WO PCT/GB1991/000484 patent/WO1991015572A1/en not_active Ceased
- 1991-03-28 IL IL9772091A patent/IL97720A/en not_active IP Right Cessation
- 1991-03-28 MY MYPI91000506A patent/MY130001A/en unknown
- 1991-03-28 NZ NZ237616A patent/NZ237616A/en unknown
- 1991-03-28 HU HU9203098A patent/HU217776B/hu unknown
- 1991-03-28 ZA ZA912397A patent/ZA912397B/xx unknown
- 1991-03-28 JP JP3506347A patent/JP3054440B2/ja not_active Expired - Lifetime
- 1991-03-28 DK DK91906493.1T patent/DK0524205T3/da active
- 1991-03-28 IE IE103791A patent/IE911037A1/en not_active IP Right Cessation
- 1991-03-28 EP EP91906493A patent/EP0524205B1/de not_active Expired - Lifetime
- 1991-03-28 TW TW080102452A patent/TW205567B/zh active
- 1991-03-28 AT AT91906493T patent/ATE157397T1/de not_active IP Right Cessation
- 1991-03-28 CA CA002079463A patent/CA2079463C/en not_active Expired - Lifetime
- 1991-03-28 KR KR1019920702407A patent/KR100202771B1/ko not_active Expired - Lifetime
- 1991-03-28 DE DE69127440T patent/DE69127440T2/de not_active Expired - Lifetime
1994
- 1994-12-07 US US08/350,741 patent/US5804194A/en not_active Expired - Lifetime
1995
- 1995-06-05 US US08/463,875 patent/US5980907A/en not_active Expired - Fee Related
1997
- 1997-11-05 GR GR970402896T patent/GR3025258T3/el unknown

Also Published As

Publication number	Publication date
IE911037A1 (en)	1991-10-09
MY130001A (en)	2007-05-31
DE69127440D1 (de)	1997-10-02
HUT65496A (en)	1994-06-28
CA2079463A1 (en)	1991-10-01
EP0524205B1 (de)	1997-08-27
DK0524205T3 (da)	1997-10-27
HU9203098D0 (en)	1992-12-28
JPH05507842A (ja)	1993-11-11
ATE157397T1 (de)	1997-09-15
IL97720A0 (en)	1992-06-21
DE69127440T2 (de)	1998-01-02
EP0524205A1 (de)	1993-01-27
WO1991015572A1 (en)	1991-10-17
HU217776B (hu)	2000-04-28
ES2106776T3 (es)	1997-11-16
GB9007194D0 (en)	1990-05-30
JP3054440B2 (ja)	2000-06-19
GR3025258T3 (en)	1998-02-27
AU7541791A (en)	1991-10-30
US5804194A (en)	1998-09-08
NZ237616A (en)	1994-03-25
CA2079463C (en)	2002-03-05
US5980907A (en)	1999-11-09
AU659995B2 (en)	1995-06-08
KR100202771B1 (ko)	1999-06-15
TW205567B (de)	1993-05-11
ZA912397B (en)	1992-11-25

Legal Events

Date	Code	Title
1999-10-28	FF	Patent granted
2000-06-01	KB	Patent renewed
2001-06-14	KB	Patent renewed
2005-05-17	KB	Patent renewed
2009-09-15	KB	Patent renewed
2011-12-29	EXP	Patent expired

Publication	Publication Date	Title
EP0524205B1 (de)	1997-08-27	Lebende vakzine
EP0400958B1 (de)	1995-09-13	Lebende Impfstoffe
JP3004049B2 (ja)	2000-01-31	病原性のないｐｈｏＰ型微生物を含有するワクチン
EP0315682B1 (de)	1993-12-22	Avirulente mikroben und deren verwendungen
EP0563311B1 (de)	2000-03-15	Verbesserte impfstoffe
AU619519B2 (en)	1992-01-30	Vaccines
HUP0201117A2 (en)	2002-08-28	Attenuated microorganisms for the treatment of infection
HK1000469B (en)	1998-03-27	Vaccines
Chatfield et al.	1993	The development of oral vaccines based on live attenuated Salmonella strains
US5811105A (en)	1998-09-22	Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway
AU659995C (en)	1997-12-18	Live vaccines